Physician profile
Krishdeep Chadha
NPI 1619147915
$6,974.17
in general payments reported to CMS, 2019-2025
25 companies · $2,648 in 2025
The $2,648 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $2,338 · 2021: $94.50 · 2022: $513 · 2023: $566 · 2024: $327 · 2025: $2,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,613 · Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,612.50 |
| Food and Beverage | $927.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Medical Systems Corporation | $2,612.50 | 2025 | Evis Exera III Duodenovideoscope, Disposable Hot Biopsy Forceps |
| Redhill Biopharma INC. | $2,261.76 | 2020 | |
| Abbvie INC. | $515.95 | 2019-2024 | Mavyret, Linzess, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.82 | 2019-2024 | Trulance, Xifaxan |
| Boston Scientific Corporation | $297.96 | 2019-2023 | Eluvia |
| Gilead Sciences, INC. | $194.81 | 2019-2022 | |
| Celgene Corporation | $110.94 | 2022-2024 | Zeposia |
| Genzyme Corporation | $82.67 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $61.18 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.79 | 2019-2024 | Entyvio |
| Ironwood Pharmaceuticals, INC | $46.84 | 2019-2022 | |
| Braintree Laboratories, INC. | $45.43 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $42.84 | 2022-2025 | Dupixent |
| Olympus America INC. | $42.37 | 2023-2025 | Endoclot Phs |
| Ferring Pharmaceuticals INC. | $39.84 | 2022-2023 | Rebyota |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $31.86 | 2024 | Simponi Aria, Tremfya, Stelara |
| Fresenius Kabi USA, LLC | $30.85 | 2023 | |
| Ucb, INC. | $21.03 | 2019 | |
| Lucid Diagnostics INC. | $20.92 | 2022 | |
| Qol Medical, LLC | $18.37 | 2019 | |
| Medtronic, INC. | $17.43 | 2023 | Gi Genius |
| Ambu INC. | $16.05 | 2022 | |
| Aimmune Therapeutics, INC. | $14.88 | 2024 | |
| Shionogi INC | $14.61 | 2019 | |
| Medtronic USA, INC. | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishdeep Chadha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.